Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.

被引：0
|
作者：
Hurtado, Alicia
Garcia-Donas, Jesus
Garrigos, Laia
Lainez, Nuria
Redondo, Andres
Fernando Cueva, Juan
Santaballa, Ana
Jesus Rubio, Maria
Palaclo, Isabel
Bover, Isabel
Antonio Lopez-Guerrero, Jose
Prieto, Mario
Garcia-Casado, Zaida
Hernando Polo, Susana
Romero, Nuria
Grande, Enrique
机构：
[1] Hosp Univ Fdn Alcorcon, Alcorcon, Spain
[2] Ctr Integral Oncol Clara Campal, Madrid, Spain
[3] Hosp del Mar, Barcelona, Spain
[4] Complejo Hosp Navarra, Pamplona, Spain
[5] Hosp Univ La Paz, Madrid, Spain
[6] Complexo Hosp Univ Santiago de Compostela, Santiago De Compostela, Spain
[7] Hosp Univ La Fe, Valencia, Spain
[8] Politecn La Fe, Valencia, Spain
[9] Hosp Reina Sofia Cordoba, Cordoba, Spain
[10] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain
[11] GEICO, Mallorca, Spain
[12] Son Llatzer Univ Hosp, Mallorca, Spain
[13] Inst Valenciano Oncol, Mol Biol Lab, Valencia, Spain
[14] Ctr Integral Oncol Clara Campal, Madrid, Spain
[15] Fdn Inst Valenciano Oncol, Valencia, Spain
[16] Hosp Univ Ramon Y Cajal, Dept Med Oncol, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps5626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5626
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
    Jermann, M
    Stahel, RA
    Salzberg, M
    Cerny, T
    Joerger, M
    Gillessen, S
    Morant, R
    Egli, F
    Rhyner, K
    Bauer, JA
    Pless, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (04) : 533 - 539
  • [22] A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
    Monika Jermann
    Rolf A Stahel
    Marc Salzberg
    Thomas Cerny
    Markus Joerger
    Silke Gillessen
    Rudolf Morant
    Fritz Egli
    Kaspar Rhyner
    Jean A Bauer
    Miklos Pless
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 533 - 539
  • [23] Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
    Hussain, Maha
    Corn, Paul G.
    Michaelson, M. Dror
    Hammers, Hans J.
    Alumkal, Joshi J.
    Ryan, Charles J.
    Bruce, Justine Y.
    Moran, Susan
    Lee, Shih-Yuan
    Lin, H. Mark
    George, Daniel J.
    CLINICAL CANCER RESEARCH, 2014, 20 (16) : 4218 - 4227
  • [24] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [25] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
  • [26] Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
    Agus, D. B.
    Stadler, W. M.
    Shevrin, D. H.
    Hart, L.
    MacVicar, G. R.
    Hamid, O.
    Hainsworth, J. D.
    Gross, M. E.
    Wang, J.
    de Leon, L.
    MacLean, D.
    Dreicer, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).
    Grivas, Petros
    Vogelzang, Nicholas J.
    Alva, Ajjai Shivaram
    Feyerabend, Susan
    Loriot, Yohann
    Necchi, Andrea
    Gupta, Sumati
    Josephs, Debra Hannah
    Rodriguez-Vida, Alejo
    Srinivas, Sandy
    Zakharia, Yousef
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Simmons, Andrew
    Nepert, Dale L.
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer
    Haddad, R. I.
    Krebs, A. D.
    Vasselli, J.
    Paz-Ares, L. G.
    Robinson, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
    Richardson, Gary Edward
    Al-Rajabi, Raed
    Uprety, Dipesh
    Hamid, Anis
    Williamson, Stephen K.
    Baranda, Joaquina
    Mamdani, Hirva
    Lee, Ya-Li
    Li, Li
    Wang, Xingli
    Dong, Xunwei
    CANCERS, 2023, 15 (09)
  • [30] An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)
    Xu, J.
    Li, J.
    Bai, C. M.
    Xu, N.
    Zhou, Z. W.
    Li, Z. P.
    Zhou, C. C.
    Wang, W.
    Li, J.
    Qi, C.
    Hua, Y.
    Su, W. G.
    NEUROENDOCRINOLOGY, 2017, 105 : 228 - 228
12345